A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and Sex

Phase 1 Completed 75 enrolled Astellas Pharma Inc

RandomizedCrossoverOpen-labelBasic science

Summary

Young and elderly, male and female subjects are each given 2 different doses of mirabegron for 7 days each. Levels of mirabegron in the blood are assessed.

Timeline

Start: 2009-03
Primary completion: 2009-11
Completion: 2009-11

Publications

Background Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, van Marle S, Kerbusch V, van Gelderen M. Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther. 2012 Oct;34(10):2144-60. doi: 10.1016/j.clinthera.2012.09.010.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mirabegron	Other / unclassified	—	Oral

Indications

No indication recorded.